Medical News

RSS

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

BioAlliance Pharma announces oral communication of Livatag Phase II trial results on liver cancer

BioAlliance Pharma SA, a company dedicated to specialty and orphan oncology products, today announces oral communication of the Phase II clinical trial results of its orphan product Livatag at the annual congress of ILCA, the only international organization devoted exclusively to liver cancer research with participation of worldwide best specialists.

6 Sep 2011

Romney faces Tea Party critics, especially on health care

Mitt Romney, the former Massachusetts governor, tried to bridge the gap between himself and the Tea Party on Monday morning, telling a gathering of supporters that the differences between the Tea Party and traditional Republicans were not as wide as many people seem to believe. Mr. Romney's critics in the Tea Party say that his record as governor of Massachusetts – notably his passage of a universal health care law that has been likened to the federal legislation passed by President Obama – does not jibe with Tea Party principles. Mr. Romney did not address that criticism directly on Sunday.

6 Sep 2011

Researchers discover novel way to increase amounts of antibiotics

A novel way of increasing the amounts of antibiotics produced by bacteria has been discovered that could markedly improve the yields of these important compounds in commercial production. It could also be valuable in helping to discover new compounds. With the ever-growing threat from antibiotic resistance, these tools will be very useful in ensuring that we have enough of these useful compounds in the future.

5 Sep 2011

DiaGenic allots options to employees

According to the resolution by the Annual General Meeting on 23 May 2011, the Board of Directors in DiaGenic ASA today allotted options to DiaGenic employees. The share options have strike price of NOK 6.00 per share, which is set based on last week weighted share price + 10%. The options have life of 4 years and can be exercised after 3 years.

5 Sep 2011

'Shan Song' finds new way of processing non-genetically modified soybeans

How much did you know about soybeans? How did you find the difference between GM soybeans and non-GM soybeans? How can people find the 'New Market' for traditional non-GM soybeans? You may get the answer if you knew 'Shan Song'.

5 Sep 2011

Cancer cells with specific genetic defect extra susceptible to therapy that damages DNA

Using a strategy based on treating cancer cells that carry a specific genetic signature - hyper-expression of the protein Myc - with therapy that affects the stability of the cell's DNA, more effective results can be achieved.

5 Sep 2011

Study aims to describe and understand current issues on OTC medicine addiction

A report of a study investigating over the counter medicine (OTC) abuse published by the Pharmacy Practice Research Trust provides evidence that there is a group of individuals experiencing a range of problems often with codeine-based medicines purchased from pharmacies, and for whom help and support varied.

5 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011

Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

5 Sep 2011

Study sheds new light on the state of Europe's mental and neurological health

A major landmark study released today by the European College of Neuropsychopharmacology (ECNP) sheds new light on the state of Europe's mental and neurological health.

5 Sep 2011

Alcohol related teen hospitalizations higher in areas with more off-licenses: Study

New research shows that the more off-license stores a town boasts of, the greater the number of under-age drinkers who are likely to end up in hospital as a result of harmful drinking.

5 Sep 2011

Asbestos related cancer risk rises after home renovations: Study

A third wave of asbestos-related cancers is emerging as the rate of malignant mesothelioma caused by exposure to asbestos during home renovations increases dramatically, according to new research.

5 Sep 2011

Autism diagnosis by brain scan a possibility

A team of Stanford scientists have found that the brains of autistic children have a distinctive topography and could be captured using new imaging techniques. This could someday create a template for the autistic brain that could be used to diagnose kids at a very early age they claim.

5 Sep 2011

Stem cell therapy for baldness

Researchers have found that molecular signals from stem cells within the skin's fatty layer trigger hair growth in mice. This could mean new treatments for baldness in people.

5 Sep 2011

Circumcision rates decline in the US: Study

A new study has shown that circumcision rates among US baby boys have fallen. According to the Centers for Disease Control and Prevention (CDC), which published the study in the Morbidity and Mortality Weekly Report, circumcision rates dropped from around 62 percent in 1999 to 57 percent in 2008.

5 Sep 2011